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Abstract
Background: dsd-LIFE is a comprehensive cross-sectional clinical outcome study of individuals with disorders/
differences of sex development (DSD). This study focuses on various rare genetic conditions characterized by
impaired gonadal or adrenal functionality.
Methods/Design: The study aims to assess quality of life (QoL) as a measure of psychosocial adaptation,
psychosexual and mental health aspects as major outcomes. Health status and functioning, medical and
surgical therapies, participants’ views on health care, psychological and social support, sociodemographic
factors and their interrelations will be investigated as factors associated with the outcomes. In addition, ethical
considerations in the field of DSD are addressed and previous experiences with health care were gathered.
One thousand and forty participants with different DSD conditions were recruited by 14 study centres in 6
European countries (France, Germany, the Netherlands, Poland, Sweden and the United Kingdom) from
February 2014 until September 2015. The conditions included were: Turner syndrome (n = 301); 45,X0/46,XY
conditions (n = 45); Klinefelter syndrome (n = 218); 47,XYY (n = 1); 46,XY gonadal dysgenesis/ovotestes
(n = 63); complete androgen insensitivity (CAIS) (n = 71); partial androgen insensitivity (PAIS) (n = 35) and
androgen synthesis disorders (n = 20); severe hypospadias (n = 25); other or non-classified 46,XY DSD (n = 8);
46,XX congenital adrenal hyperplasia (CAH) (n = 226); 46,XX gonadal dysgenesis/ovotestis (n = 21); and 46,XX
in males (n = 6). For an add-on study, 121 46,XY male-assigned individuals with CAH due to 21-hydroxylase
deficiency were recruited. Mean age of participants’ was 32.4 (+/− 13.6 years).
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Discussion: Participation was high in conditions not commonly described as DSD, such as Turner and
Klinefelter syndromes or CAH. Recruitment of individuals with XY DSD conditions proved to be more difficult.
The data collection of PROs resulted in high data quality. Within medical and physical examination data, more
missings and/or inaccurate data were found than expected. The European dsd-LIFE study recruited and
evaluated the largest cross-sectional sample of individuals with different conditions classified under the term
DSD. The data from this large sample will provide a sufficient basis for evidence-based recommendations for
improvement of clinical care of individuals affected by a DSD condition.
Trial registration: German Clinical Trials Register DRKS00006072.
Keywords: Disorders of sex development, Differences of sex development, DSD, Sexual differentiation,
Interdisciplinary care, European network
Background
Rare conditions – Disorders/differences in sex
development
“Disorders/differences of sex development (DSD)” is
used as an umbrella term for various rare conditions
that are characterized by an incongruence of chromo-
somal, gonadal and genital sex development. The
approximate incidence of genital anomalies is estimated
to occur 1:4500 live births [1].
The term DSD and a new system for nomenclature
were introduced by the Chicago Consensus Group in
2005, replacing previous nomenclature that was perceived
negatively by affected individuals. The classification of
DSD distinguishes three major groups: (1) DSD with
atypical sex chromosome configurations, including Turner
syndrome (45,X0 and mosaicisms), Klinefelter syndrome
(47,XXY and mosaicisms) and conditions with 45,X/46,XY
or 46,XX/46,XY karyotypes; (2) XY DSD, encompassing
conditions characterized by 46,XY karyotype and impair-
ment of testicular development, androgen biosynthesis or
action, AMH biosynthesis or action, hypospadias, cloacal
exstrophy and other syndromic forms; (3) XX DSD,
comprising conditions characterized by 46,XX karyotype
and androgen excess, such as congenital adrenal hyperpla-
sia, P450 oxidoreductase deficiency, aromatase deficiency
or exogenous causes, impairment of ovarian, uterine or
vaginal development and other syndromic forms [1]. The
multitude of mechanisms related to sex determination
and sex differentiation—such as genes involved in gonadal
development, androgen receptor function and steroid
biosynthesis—makes the diagnoses of the XY DSD group
complex and challenging. The heterogeneity of clinical
presentations of DSD conditions results in variations of
treatment options, including medical, surgical or psycho-
therapeutic, while their rarity carries the consequence of
limited ad hoc knowledge about those various options
[2–6]. Clinical studies on DSD are often single-centre
experiences from regional samples with a limited number
of unambiguous diagnoses of participants, and many
of the studies lack appropriate comparison groups.
The comparability of these studies is often impeded
because different definitions and study methodologies
are used [7–19].
The study dsd-LIFE, funded by the European Commis-
sion (7th Framework Programme, FP7), has sought to
overcome some of the above-mentioned challenges by
using a standardized and consistent study methodology
in a large number of individuals with DSD conditions in
six European countries.
Methods/Design
The dsd-LIFE study
dsd-LIFE investigates and compares the long-term out-
comes of surgical and hormonal therapy and psycho-
logical and social support in adequate numbers of
adolescents (from the age of 16) and adults with DSD
conditions, aiming to provide the basis for improve-
ments in evidence-based recommendations for care. The
long-term impact of the study is expected to result in
improvement of care and subsequently higher overall
quality of life (QoL) and better integration and partici-
pation of individuals with DSD in society. To reach
these aims, we assessed as main outcomes QoL, psycho-
sexual and mental health aspects. As determinants we
collected objective data on sociodemographic factors,
social participation, religion, culture, physical and mental
health, risk for mental health such as anxiety, depression,
autism and ADHD, treatments such as genital surgery
and hormone therapy, fertility, psychological and social
support, current and past health care, psychological
factors such as self-esteem, coping, autonomy, attach-
ment and subjective appraisal of relationships as well
as appraisal of relations and personal’ views on ethics
of care (Fig. 1).
The dsd-LIFE consortium consists of 16 European
partners from Germany, France, the Netherlands,
Poland, Sweden and the United Kingdom (UK). Fourteen
of these partners acted as recruiting sites, including
Berlin, München, Lübeck, Münster (D), Paris, Lyon
Montpellier and Toulouse (F); Amsterdam and Nijmegen
Röhle et al. BMC Endocrine Disorders  (2017) 17:52 Page 2 of 26
(NL); Lodz and Warszawa (P); Stockholm (S); and
Birmingham (UK) (Fig. 2). In addition to the recruiting
sites, the consortium included one centre with expertise
in medical ethics (Göttingen) and one partner with
expertise in European community (EC) project manage-
ment (München). The Scientific Advisory Board consisted
of international experts in the fields of endocrinology,
psychology, surgery, and ethics and a representative
of a longstanding patient support group for androgen
insensitivity syndrome. An important scientific basis for
this study was the results of a German network DSD
study published in 2009, which was the largest clinical
evaluation study of DSD available at the time [20].
In this paper, we outline the theoretical and methodo-
logical framework of the study. We compare the study
aims related to participation rates and data quality to the
actual sample recruited and the information that became
available from various sources.
Conceptual model, study design and methods
Conceptual model
Historically, clinicians, administrators, researchers, and
policy makers have evaluated the effectiveness of treat-
ments and interventions with little input from patients.
With the rising participation of patients and clients in
shared decision making, evaluation of the impact of care
on day-to-day life has become increasingly important.
When validated questionnaires are administered directly
to participants without involving clinicians, they are
called patient-reported outcomes (PROs) and may in-
clude reports on objective parameters such as socio-
demographic factors, measures of functioning and health
status as well as subjective appraisal of one’s QoL and
other relevant aspects of well-being. Conceptually, dsd-
LIFE developed a framework to determine the major
outcome QoL solely from the subjective perspective of
the participant and adopted the definition of health pro-
posed by the World Health Organization (WHO),
namely, physical, psychological and social well-being
(Fig. 1) [21, 22]. For each dimension of QoL, dsd-LIFE
sought to collect information from at least one add-
itional perspective. For physical health, dsd-LIFE aimed
to collect data from clinicians through medical histories,
clinical examinations and data documented in medical
records. For psychological health, we probed for indica-
tors of special health care needs, clinical diagnoses and
screening instruments of mental health conditions. For
social well-being, we collected information on sociode-
mographics, participation and inclusion [21, 22]. For
satisfaction with health care, we measured the subject-
ive rating of the participants of the care they had
received, such as satisfaction with medical and psycho-
logical care, medical information management, patient-
centred care and doctors’ behaviour. To relate outcomes
to treatments, we collected medical data of current and
past treatments and interventions from medical files as
available. The overall aim of the study was to improve
health care in the clinical population of individuals with
DSD conditions.
Study design
dsd-LIFE was designed as a non-interventional, clinical,
cross-sectional study. The inclusion criteria covered all
conditions described as DSD in the classification system
of the Chicago Consensus Conference and an age of
16 years or older. Verification of the correct diagnosis
was conducted by examining clinical medical and gen-
etic data; all participants had to be seen at least once at
one of the recruiting sites. Health status was assessed by
Fig. 1 Conceptual model
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a physical examination, potentially augmented by further
examinations. Current and past treatment data were
obtained from a medical interview and medical chart
review. The wide age range of the subjects allowed assess-
ment and comparison of treatments that were typical in
certain decades but changed over time. PRO data came
mainly from an online survey, allowing privacy and
confidentiality for all participants. The design was chosen
to allow the analysis of associations of treatments and
interventions experienced in the past with contemporary
QoL, physical and mental health, psychosexual functioning
and satisfaction with care. In addition, we sought to exam-
ine participants’ views and perspectives on the ethics of
general health care and controversial treatments (Fig. 3).
We did not recruit a comparison or control group, but
results of major outcomes will be compared to reference
data. Moreover, we planned to use group comparisons of
the diagnoses within the sample because some issues
such as e.g. fertility or psychosexual problems are, to
varying degrees, issues for all people affected by DSD.
Instruments
The use of available, standardized instruments with ref-
erence data from the general population was preferred
whenever possible, thus allowing comparisons to the
general population, specifically in the areas of sociode-
mographics, QoL and screening measures of physical
and mental health, psychosexual outcome, psychological
factors and overall satisfaction with health care. For
specific aspects of DSD, we included “self-constructed”
items. The iterative review of the suggested instruments
and measurements was performed by experienced pa-
tient support group representatives and by the project’s
Advisory Board.
Fig. 2 Locations of project partners. The following centres participated in the study: France: Université Claude Bernard Lyon; Le Centre Hospitalier
Universitaire Montpellier; Université Paris-Sud, Paris; Le Centre Hospitalier Universitaire de Toulouse. Germany: Charité Universitätsmedizin Berlin;
Ludwig-Maximilians-Universität, München; University of Lübeck; Universitätsmedizin Göttingen; Westfälische Wilhelms-Universität Münster. Poland:
Medical University of Lodz; Children’s Memorial Health Institute, Warszawa. Sweden: Karolinska Institutet, Stockholm. United Kingdom: University
of Birmingham. The Netherlands: VU University Medical Center, Amsterdam; Radboud University Nijmegen Medical Center, Nijmegen
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For application of the final questionnaire in all study-
relevant languages (Dutch, English, French, German,
Polish, and Swedish), professional translation of the
instruments used was required. To some extent, the
standardized instruments chosen were available in the
languages needed (Table 1). For those instruments and
(self-constructed) items that required translation, we
followed the linguistic validation process of the inter-
national translation guidelines [23, 24].
Medical interview, retrospective chart review and medical
examinations (part 1)
Generally, the data came from a personal medical review
on contemporary signs and symptoms, past medical
history and a physical examination with a physician;
the data were input by a study nurse or physician
(case report form; CRF):
1. The medical interview (239 items) collected
standardized information on the diagnosis, karyotype
and comorbidities of the participants and their
families, physical activity, smoking behaviour,
current therapy, application, therapy monitoring,
previous hormone therapies and psychological
counselling and menstruation.
A retrospective chart review of past diagnosis and
medical treatment was performed to obtain information
from medical records, including birth history and genital
phenotype at diagnosis, date of diagnosis, and hormones
and hormone therapy at diagnosis (dosage, application)
(79 items). Previous surgical procedures and complica-
tions were also retrieved from medical records (29 items).
Further retrospective data related to hormone treatment
were gathered from medical records at the time of puberty
(Tanner stage II) (6 items) and completion of puberty
(> = 16 years) (45 items). For individuals with congenital
adrenal hyperplasia (CAH), additional data on hormone
therapy were taken from the records at the ages of
9 months and 6 years to evaluate steroid hormone levels
and treatment outcomes (30 items each). Moreover,
descriptions of ambiguity of genitalia (44 items) were
gathered from the records, if applicable.
2. The general physical exam was used to obtain a
general impression of the patient; anthropometric
measures of height, weight, body mass index (BMI),
and hip and waist circumference; and blood pressure
(mean of 3 measurements). The exam also revealed the
presence of acanthosis; stretch marks; acne; hirsutism;
decrease of body hair; bruised skin; and pubic hair.
Breast development was assessed according to the
Tanner and Ferriman Galway score (13 items).
3. An optional gynaecological/urological examination,
including a gynaecological history if applicable, general
genital development and surgical results, was performed
for participants who had undergone genital constructive
surgery (11 gynaecology/9 urology items).
4. The laboratory investigations featured blood
tests that used a fasting blood sample to measure
Fig. 3 Study design and work packages of dsd-LIFE
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metabolic parameters such as lipids, glucose, insulin,
R-Homa, liver enzymes, uric acid, whole blood
count, and renal parameters for all diagnostic groups;
hormones in all females: gonadotropins, oestrogen,
androgens, and thyroid function; hormones in all
males: gonadotropins, oestrogen, androgens, anti-
muellerian hormone (AMH), inhibin B and thyroid
function; and hormones in all participants with CAH,
including 17-hydroxyprogesterone, androstenedione,
and renin. In participants with gonads in place, AMH,
inhibin B and gonadal tumour markers were
measured (38 items).
5. The optional technical assessments included
dual-energy X-ray absorptiometry (Dexa-scans)
measuring bone mineral density and body composition
(15 items); bioelectrical impedance analysis (BIA)
evaluating body composition (12 items); ultrasound
of the carotic artery measuring intima media thickness
(IMT) (9 items); ultrasound of the uterus and ovaries
estimating uterine size to evaluate the development and
oestrogen effects and the ovarian structure and possible
abnormalities; testicular ultrasound measuring the
testicular size and structure and possible abnormalities
(57 items); and a spermiogramme evaluating sperm
quality (count, motility, morphology, vitality, and
volume) (6 items).
Patient-related outcomes (PROs, part 2)
This part of the study included standardized instruments
and self-constructed questionnaires (Table 1).
1. Sociodemographic data such as age, area of
dwelling, education, household and family,
occupation, nationality, religious denomination and
social participation were gathered according to the
European Social Survey (ESS; source questionnaire
amendment 01, 2012/2013). All questions were
provided in interview format to maximize the
accuracy and objectivity of the information. For
dsd-LIFE, we transformed these questions into
self-reporting questionnaires, retaining the response
format. Validated translations and reference data
are available for all countries of the dsd-LIFE
consortium (http://www.europeansocialsurvey.org).
2. For the assessment of QoL, we used theWHOQOL-
BREF, which evaluates physical and psychological
QoL, social relationships, environment and global
QoL; reference data on both the general population and
clinical samples for comparison are available [25, 26].
3. To assess physical health we used questions from
the European Health Interview Survey (EHIS) and
self-constructed condition specific questions.
4. To evaluate mental health we used questions from
the EHIS and self-constructed questions. We used
the Hospital Anxiety and Depression Scale (HADS)
to screen for depression and anxiety. We used the
Autism Spectrum Quotient (AQ)-10 test and the
Adult ADHD Self-Report to screen for signs and
symptoms of for autism and ADHD as they have
been described as common comorbidities in the
DSD population in previous studies [27, 28].
5. To asses psychological factors the following
questionnaires were chosen: the Rosenberg
Self-esteem Scale (RSES) for self-esteem,
a self-constructed questionnaire for shame,
stigma and coping, questions form the ESS
for autonomy, the Relationship Structures
(ECR-RS) Questionnaire for attachment.
6. Psychosexual issues were evaluated by standardized
and condition-specific self-contructed questionnaire.
The Body Image Scale (BIS) was chosen to investi-
gate body satisfaction, an issue of high relevance in
the condition groups studied [29, 30].
We opted to evaluate gender dysphoria with
the well-established and relatively short Utrecht
Gender Dysphoria Scale (UGDS). This instrument
has been developed for the assessment of people
without DSD who have gender identity disorder
but has been used in previous studies in DSD [31].
In addition, feelings of male- and femaleness
were evaluated by two self-constructed questions.
We chose not to evaluate gender role behaviour,
which shows a wide variation in the normal
population and does not have clinical relevance
in itself.
The questionnaire on sexuality was developed for
the German network study evaluating developmental
milestones sexual problems, feelings and satisfaction
with sexual life. The items had performed positively
in that study, and the scale was thus selected and
translated into the various languages for dsd-LIFE
[10, 32]. Sexual orientation was measured with
the Kinsey scale, and the wording was changed to
make the questions less dichotomous in terms of
gender [33, 34].
7. For evaluation of satisfaction with health care,
the Client Satisfaction Questionnaire (CSQ4) and
an adapted version of the Child Health Care –
Satisfaction, Utilization, and Needs Questionnaire
(CHC-SUN) was chosen. The CHC-SUN was originally
developed as a proxy-report version for parents of
children with chronic conditions and later adapted
and tested as a self-report version for young
adults with chronic diseases. For this study,
an extended short form of the CHC-SUN was
applied, and several self-constructed items on
satisfaction with care and needs were added [35, 36].
For assessment of current and past health care,
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satisfaction with information management,
satisfaction with hormone therapies, genital surgery,
current and previous treatment/psychological/social
support and fertilty self-constructed questions
were used.
8. Participants’ perspectives on ethical issues were
assessed by self-constructed questionnaires. The
items on ethical issues had been developed by the
ethical research group in Göttingen based on
qualitative work with focus groups and individual
interviews. The interview questions were closely
related to the recommendations for care of individuals
with DSD, which were developed by the German
Ethical Council in 2012 [37, 38]
Obligatory requirements for participation in the
study were participation in the medical clinical inter-
view and completion of the PRO questionnaire. Medical
examinations were considered an important part of the
study but were not obligatory. Participants not interested
in medical examinations were included into the study
if they met the above requirement, if they had visited
the centre in person at least once, and if they had
documented previous clinical consultations and diag-
nosis (Fig. 4).
Inclusion criteria
The study included individuals with a confirmed diagnosis
of DSD with variants in sex chromosomes, including
Turner syndrome, Klinefelter syndrome and mixed go-
nadal dysgenesis (45,X/46,XY); XY conditions, including
testicular dysgenesis, impairment of testosterone synthesis
or action and hypospadias; XX conditions, including ovar-
ian dysgenesis, congenital adrenal hyperplasia (CAH), and
XX males; and ovotesticular DSD. XY male participants
with CAH (21-OHD and 11ß-HSD deficiency) were in-
cluded, although, according to the definition, they do not
belong to the DSD classification. This group was an add-
on study population because it was hypothesized that in
many ways these subjects might face similar problems as
persons within the DSD classification, such as e.g. sex
hormone imbalances and fertility problems. Participants
had to be at least 16 years old with a medically confirmed
clinical and/or genetic diagnosis (Fig. 4). The age limit of
16 years was chosen because pubertal development is
essential for the evaluation of psychosexual development.
Moreover, the initial effects of treatment in childhood and
adolescence on the metabolic system can be evaluated at
the beginning of adulthood. In addition, the perspectives
of adolescents regarding their DSD condition and treat-
ment are of particular interest.
Exclusion criteria
Individuals not fulfilling the diagnostic criteria or incap-
able of giving consent or answering the questions on their
own were excluded. Subjects with Mayer-Rokitansky-
Küster-Hauser syndrome (uterus agenesis) and other
complex non-endocrine urogenital malformations were
also excluded as most centers had no access to patients
with these diagnoses.
Ethics
Ethical approval was first sought from the medical ethics
committee at the Charité Universitätsmedizin Berlin.
Ethical approvals were subsequently sought from the
other study centres. Data protection and valid procedures
to secure the anonymity of the participants were crucial
requirements of the study and for the ethical approval.
Fig. 4 Study procedure
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Dsd-LIFE participants were informed thoroughly about
the study content, aims and potential risks and subse-
quently gave written informed consent. The informed
consent was written in lay language to ensure the under-
standability of the aims, procedures and potential risks of
participation. All participants had to consent to the release
of their medical data retrieved from medical charts, in-
cluding genetic test results. If the participant was under-
age, both the potential participant and the parents of the
participant had to give written informed consent.
The opportunity for withdrawal from the study was pos-
sible at any stage of the study. Travel costs of the partici-
pants were covered upon request. According to the World
Medical Association’s Helsinki Declaration and the Council
of European Convention on Human Rights and Biomedi-
cine [39], dsd-LIFE posed minimal risk for the participants
(e.g., medical exams, blood sampling) [40, 41].
Recruitment
The 14 recruiting centres approached former and
current patients with a diagnosis meeting the inclusion
criteria for dsd-LIFE and promoted participation in the
study in various additional ways. The means of contac-
ting potential study participants included regular mail,
e-mail, phone, direct contact of the physician (at con-
sultation hours at the recruitment site or at consultation
hours of regional endocrinologists linked to the recruit-
ment site), patient support groups and information from
the dsd-LIFE website (www.dsd-life.eu). A standardized
record was kept by each centre to document the recruit-
ment procedure and the informed consent process. In
this way, the process of individual approach and infor-
mation about acceptance or denial of participation and
inclusion were retained. Participant recruitment started
on February 1, 2014 and ended on September 30, 2015.
To obtain adequate numbers in the XY DSD group,
recruitment for this group was prolonged from 16 to
20 months.
Study logistics
Each recruiting centre established a team to contact,
include and monitor participants throughout the study.
Study teams could consist of endocrinologists, gynae-
cologists, urologists, surgeons, psychologists, and study
nurses: usually, the endocrinologist informed the potential
participant, assured or verified consent and subsequently
performed the medical examination. Gynaecologists, urol-
ogists or surgeons accomplished the gynaecological or
urological examinations as required and if the participant
had consented to these examinations. All clinicians pro-
vided counselling for treatment options if needed or ar-
ranged for appropriate referrals. The study nurse or
physician entered the data of the medical CRFs.
The PRO was explained by the study nurse. To ensure
confidentiality and unbiased responses, participants were
asked to respond to the online version of the PRO,
which was accessible only with a secure password in the
recruitment centres. A physician, and when possible a
psychologist, was available for questions and to support
the participant at any time during the study. In case the
participant was not able or willing to complete the PRO
at the recruitment centre, online access was provided for
answering the questions at home. If needed, a paper-
and-pencil version was provided for the participant, and
data entry was accomplished by the study nurse after the
patient had completed the questions.
Training and quality management
All of the study procedures, beginning with enrolment,
were set up according to standard operation procedures
(SOP). Each recruitment team received digital and
printed booklets with the SOPs and was trained before
recruitment started. The training occurred either face-
to-face in a local study centre or via Skype conferences.
The training and the SOPs addressed all relevant study
procedures, including the inclusion or exclusion criteria;
organizational aspects (patient information, informed
consent, pseudonymization of data, maintenance of study
records, patient time plan, travel reimbursement, contact
details for participants); standardized performance of
medical exams; blood sampling and biobanking; regis-
tration of core data on the diagnosis in the international
DSD patient registry, if the participant consented
(I-DSD, https://www.i-dsd.org/); administration of PROs
and CRFs; data entry; and handling of information asso-
ciated with exclusion from the study or the decision not
to approach a potential participant. Such information was
held at the discretion of the recruiting centre. For ethical
reasons and data protection, we were not allowed to enter
data on diagnosis, age or gender or other information
available from the charts in the dsd-LIFE database if the
patient had not consented to participate in the study.
Therefore, data on non-responders are not available in a
systematic manner. To ensure ongoing recruitment and
timely study performance and to ensure data quality at
data entry, the study management (Work Package 2,
Fig. 4) liaised regularly with each recruitment centre.
Data management, safety and quality
The data collected during the study were entered into a
central database using electronic data capture. The data
were entered remotely at the sites using electronic CRFs
that also allowed definition of specific roles (clinical in-
vestigator, study assistant, etc.) to control access rights
depending on the function within the study. To ensure
data safety and data privacy, personal data were
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pseudonymized. Only the study data of the participants
were stored in the study database. Personal data of the
individuals were not saved in the database at any time.
The study data could be linked to the personal data only
by using the pseudonyms, which were created automat-
ically by the system. A pseudonymization list was safely
stored in the local study centres and could be accessed
only by the local principal investigator. Data checks were
performed at regular time points (every 3–6 months)
during recruitment. At the end of data entry, the filling
status of medical data and the participant questionnaires
were checked. Data plausibility, data consistency, and
the possibility of missing data were verified. In addition,
checks were performed to identify entire empty datasets,
non-empty datasets with missing data and other implau-
sibilities and inconsistencies. Queries regarding possible
data entry errors or missing values were sent to the
clinical sites for clarification or completion, respectively.
The Coordinating Centre for Clinical Studies at the
Charité (Koordinierungszentrum für klinische Studien,
KKS Charité) performed data management and quality
assurance.
All diagnoses were verified at the end of recruitment
by the leading study centre at Charité Universitätsmedi-
zin Berlin. The complex diagnoses included in the XY
DSD and the CAH groups (B.K., M.S.-C., H. C.-G.,
A.N.) were double checked by two endocrinologists
independently. Implausibilities were discussed with the
local study centre.
Statistical analysis of the dsd-LIFE cohort
To describe the dsd-LIFE study group in detail, we first
compared the planned, recruited and participating num-
bers of participants, in total and per diagnostic group
(Fig. 4). The recruitment of individuals was described
using absolute and relative frequencies of contacted per-
sons and participants in total and per country. Information
on “recruitment ways” (the ways potential participants were
contacted) were collected from the participating sites; how-
ever, due to missing data, it was not possible to provide a
comprehensive quantitative analysis. Relevant participant
characteristics of the recruited study population were ana-
lysed descriptively in total and per country using means
and standard deviations for continuous parameters and
absolute and relative frequencies for categorical parameters.
Relevant social characteristics of the dsd-LIFE cohort
were compared with the results from the population-
based European Social Survey for the countries involved
in dsd-LIFE comparison samples [42].
To assess data quality, the number of non-responses
to entire questionnaires and sub-domains was examined
by calculating relative frequencies in the total cohort and
in the diagnostic sub-groups. Participation in the medical
examinations and the availability of retrospective data
were assessed using relative frequencies per diagnosis
group, per country and per gender where appropriate. All
computations were performed using R (Version 3.2.2) and
statistical analysis system (SAS Version 9.4).
Results
Description of study population
Recruitment
At the beginning of the project, the recruitment sites re-
ported a total number of 2519 persons with the different
DSD diagnoses currently treated in the centres or who
had been treated in the past. Based on that number and
considering loss to follow-up, exclusion criteria and
those who declined to participate, the centres estimated
1697 potential participants in 2012 (Fig. 3). However, in
the project recruitment phase (2/2014–9/2015), the
centres were able to identify and to invite 3217 potential
participants from their records, and 1161 agreed to par-
ticipate in the study (36.1%). Most of the 1161 dsd-LIFE
participants were recruited in France (n = 311, 26.8%),
followed by Germany (n = 291, 25.1%), the Netherlands
(n = 265, 22.8%), Sweden (n = 131, 11.3%), Poland
(n = 108, 9.3%), and the United Kingdom (n = 55, 4.7%)
(Table 2).
Diagnosis
Among the 1161 participants, 1040 had a DSD condition
according to the Chicago classification (Table 3), and
121 were males with 21-hydroxylase deficiency or 11-β-
hydroxylase deficiency. Five participants had to be
excluded during the verification process of diagnoses as
non-cases. Overall, the project achieved a participation
rate of 36.1%, ranging from 54.4% in Sweden to 30.0% in
the Netherlands. An overview of participation by
Table 2 Participation rate in dsd-LIFE
Study sites Contacted n = 3217 Participation n = 1161 (36.1%) Non-participation n = 2057 (63.9%)
Germany 927 291 (31.4%) 636 (68.6%)
France 676 311 (46.0%) 365 (54.0%)
The Netherlands 882 265 (30.0%) 617 (70.0%)
Poland 331 108 (32.6%) 223 (67.4%)
Sweden 241 131 (54.4%) 110 (45.6%)
The United Kingdom 160 55 (34.3%) 105 (65.7%)
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Table 3 Classification of participants according to the Chicago classification
Diagnosis group n Classification Gender Sum
Female Male Other
Sex chromosome
DSD
301 Turner syndrome
Monosomy: 45,X 150 0 0 150
Mosaics: 45,X/46,XX 31 0 0 31
Isochromosomes: 45,X/46,X,i(Xq) | 46,X,i(Xq) | 45,X/46,
X,i(Xq)/47,X,i(Xq)
59 0 0 59
Deletions: 45,X/46,X,del(X) | 46,X,del(X) 19 0 0 19
Polyploidy: 45,X/46,XX/47,XXX | 45,X/47,XXX | 45,X/46,
XX/47,XXX/48,XXXX
16 0 0 16
Ring material: 45,X/46,X,r(X) 12 0 0 12
Not classified 4 0 0 4
Unknown 10 0 0 10
45 45,X/46,XY conditions 31 14 0 45
218 Klinefelter syndrome
47,XXY 1 199 4 204
47,XXY/46,XY 0 5 1 6
47,XXY/46,XX 0 3 0 3
Other 0 3 0 3
Unknown 0 2 0 2
1 47,XYYa 0 1 0 1
XY DSD 222 XY, Complete GD 20 0 1 21
XY, Partial GD 12 25 0 37
XY, Ovotesticular DSD 3 2 0 5
CAIS 69 0 2 71
PAIS 17 18 0 35
3ß-HSD deficiency 1 1 0 2
17β-HSD III deficiency 9 0 2 11
5α-RD II deficiency 2 1 1 4
17α-hydroxylase/17,20-lyase deficiency 1 0 0 1
Unknown steroid synthesis defect 1 1 0 2
Hypospadias 0 24 1 25
XY DSD not classified 7 1 0 8
XX DSD 21 XX gonadal dysgenesis 20 0 0 20
XX ovotesticular DSD 1 0 0 1
226 CAH (21-hydroxylase deficiency)
Salt-wasting 109 2 0 111
Simple virilizing 65 1 0 66
Non-classical 33 1 0 34
not to classify 3 0 0 3
Other CAH
STAR deficiency 1 0 0 1
3β-HSD deficiency 2 0 0 2
11β-hydroxylase deficiency 5 1 0 6
POR deficiency 2 0 0 2
Unknown 1 0 0 1
6 46,XX testicular and unknown DSD 0 6 0 6
Sum 717 311 12 1040
GD gonadal dysgenesis, PAIS partial androgen insensitivity, CAIS complete androgen insensitivity, 3ß-HSD 3β-hydroxysteroid dehydrogenase, 17β-HSD III 17β
hydroxysteroid dehydrogenase III, 5α-RD II 5α-reductase II, STAR steroidogenic acute regulatory protein, POR cytochrome P450 oxidoreductase. aThe patient with
47,XYY, although not belonging to the Chicago classification, is included, as he displays gonadal dysgenesis as Klinefelter syndrome
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country is given in Table 2. From 3217 approached per-
sons, the recruitment means and respective participation
rate could be tracked for 1717 individuals. The numbers
of contacted persons/numbers of participants/participa-
tion rate were as follows: by mail: 1222/268/22%, e-mail:
40/25/63%; telephone: 91/40/44%; personal contact in
the clinic: 282/215/76%; and support groups: 82/20/24%.
Of these methods, response rates (76%) were highest
among persons who were contacted directly by their
physician. The recruitment of individuals with a diagno-
sis of sex chromosome DSD was achieved as intended,
whereas recruitment of individuals with 46,XY DSD
diagnosis and 46,XX gonadal dysgenesis diagnosis re-
sulted in approximately half the initially planned num-
bers. The diagnoses and gender and of the cohort are
described in detail in Table 3. Proportions of diagnoses
and gender are shown in Table 6. The participants with
Turner syndrome were classified according the Morten-
sen classification [43]. In the groups of participants with
Klinefelter and Turner syndrome, the clinical diagnosis
was confirmed genetically in almost all cases (>96%). In
the heterogeneous groups of diagnoses summarized
under XY DSD and XX CAH, the proportions of genet-
ically confirmed diagnoses were 47.5% and 69%, respect-
ively. However, the precise mutation responsible for the
genetic conditions was not documented in the patient
files in some centres due to insufficient or lack of trans-
mission from the genetic laboratory. (In some countries,
sharing genetic information with clinicians requires writ-
ten informed consent by the patient.) In the group of
XX gonadal dysgenesis, only clinical diagnoses were doc-
umented. Detailed information on the proportions of
genetic and clinical diagnoses is shown in Table 4. In
participants with CAH due to 21-hydroxylase deficiency
(21-OHD), the severity of the enzyme defect was classi-
fied according to the clinical phenotype. In addition, this
group was classified according to genotype because a
valid genotype-phenotype correlation could be demon-
strated. For 21-OHD, genotype-phenotype classification
was established ranging from 0 for salt-wasting for the
severest forms to C for non-classical, which is the least
severe form [44, 45]. This classification according to the
genotype of participants with 21-OHD deficiency is
presented in Table 5.
Sociodemographics
The sociodemographic characteristics of the 1040 parti-
cipants with a DSD diagnosis in the dsd-LIFE cohort
are shown in detail in Table 6. Data of the 121 males
with CAH are not shown. Missing values for sample
characteristics were generally below 10%, with no
missing data regarding age or gender and moderate
missing frequencies (>10%) for working hours per
week (290/1040, 27.9%) and feelings about household
income (164/1040, 15.8%).
The mean age of the participants was 32.4 years (SD
13.6), ranging from 25.2 (SD 10.1) in Poland to 39.4 (SD
14.7) in the Netherlands. The youngest participant was
16 years old, and the oldest was 75 years old. Compared
with the general population (ESS) in their respective
countries, the participants recruited in dsd-LIFE were
10–20 years “younger”, with the largest gap observed in
Poland (mean age of the Polish population in ESS 46.1,
SD 18.9).
In the country-specific analysis, the overall majority of
participants were living as females (ranging from 59.8%,
73/122 in Sweden to 84.3%, 231/274 in France), except
for in Poland (42.1%, 45/107), which was easily explained
by varying recruitment numbers in the different diagno-
sis groups (Table 6). Regarding citizenship, the clear ma-
jority (more than 92%) hold citizenship in the country in
which they live. This finding is very similar to the results
from the ESS. Participants of dsd-LIFE were mainly liv-
ing in large or small cities (ranging from approx. 45.3%
in Sweden to 72.0% in Poland). Compared to ESS refer-
ence data, people living in large cities and suburbs were
overrepresented in the dsd-LIFE population. Moreover,
6.4% of the participants had a migration background
(first language spoken at home was not the same as the
official language in the respective country).
Living circumstances varied among the countries
(Table 6). The total “number of people living in the
household” was similar across the study countries, with
a mean between approximately two and three persons
per household, and comparable to that of the general
population (ESS).
In France and Poland, most of the participants were
living with their parents (48.2% and 62.3%); in Sweden,
the largest group of participants lived alone (37.0%); in
Germany and the United Kingdom, the participants
equally lived alone (30.3% and 28.6%), were married
(18.5% and 23.8%) or lived with parents (30.3% and
28.6%), whereas in the Netherlands, most of the partici-
pants were married (46.1%).
Regarding education assessed via the ESS version of
the International Standard Classification of Education1
(ESISCED; ranging from 1: basic education to 7: aca-
demic degree ≥ master), 20.5% of the DSD cohort from
the dsd-LIFE cohort had a low education level (ESISCED
≤2), 46.1% had an intermediate education level
(ESISCED 3–5), and 27.0% had high education levels,
while the remaining 6.4% stated other education (e.g.,
school for children with learning difficulties). In general,
the dsd-LIFE cohort had somewhat higher education
levels than the ESS cohort with some differences across
countries. In Germany, the distribution of categories was
comparable to the ESS population, while in France, the
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Netherlands and more prominently in Sweden and the
UK, we found a pattern of higher levels of education
compared to the ESS cohort. Poland was the only
example of somewhat lower educated participants com-
pared to the general population.
Most subjects in the dsd-LIFE cohort performed paid
work (52.9%) or had spent time in educational pursuits
(16.1%) in the last 7 days. The remaining participants
were either unemployed (8.3%), permanently sick or
disabled (5.9%) or otherwise occupied in the last 7 days
(retired, in community or military service, doing
household work or other: 16.8%). This distribution was
almost the same in all dsd-LIFE countries. Compared to
the percentage reported in the ESS, the percentage of
persons in paid work was very similar (e.g., Poland:
47.9% in dsd-LIFE vs. 48.3% in ESS), and the number of
working hours per week was comparable among the
dsd-LIFE countries (approx. 32–37 h, mean 33.6, SD
12.7). However, compared to those reported in the ESS,
the number of working hours per week was 4 to 8 h less.
In the small sample from the UK, there were more
participants with full-time work and working hours
comparable to the English ESS data, indicating some re-
cruitment bias. The number of persons currently receiv-
ing education was two to three times higher in all
countries, except in Poland and Sweden, than in the ESS
(e.g., France: 18.4% in dsd-LIFE vs. 6.2% in ESS), which
was explained by the lower mean age of the study popu-
lation. In contrast, the proportion of retired people was
much smaller in the dsd-LIFE cohort (e.g., France: 0.4%
in dsd-LIFE vs. 32.0% in ESS).
Regarding household income, most of the dsd-LIFE
participants were living comfortably or coping on their
present income (both categories combined: 83.6%). This
result was found for all dsd-LIFE countries (≥ 75% for
combined categories). The results were also very similar
to the country-specific outcomes of the ESS. The
Table 5 Classification of individuals with 21-OHD (CYP21A2) and
other CAH according to genotype
Total 0 A B C No mutation or
not classified
Other CAH Sum
All 55 81 75 30 92 14 347
46,XX 31 44 42 27 70a 12b 226
46,XY 24 37 33 3 22c 2d 121
This classification includes severity of 21-OHD according to genotype. 21-OHD
shows a spectrum ranging from 0 = salt-wasting to C = non-classical when
performing genotype-phenotype correlations
aThese include no mutation (n = 68) and “not classified” (n = 2)
bThese include STAR defect (n = 1), POR deficiency (POR) (n = 2), 3ß-HSD
deficiency (HSD3B2) (n = 2), 11ß-OHD deficiency (CYP11B1) (n = 6) and
unknown other (n = 1)
cThese include only no mutation (n = 22)
dThese include 11ß-OHD deficiency (CYP11B1) (n = 2)
Table 4 Number of genetically and clinically confirmed diagnoses of XY DSD and CAH
Classification of conditions Conditions Number of participants Genetically verified diagnosis Clinical diagnosisa
Sex Chromosome DSD Turner syndrome 301 291 (96.7%) 10 (3.3%)
Klinefelter syndrome 218 216 (99.1%) 2 (0.9%)
45,X/46,XY 45 45 (100%) - (0%)
47,XYY 1 1 (100%) - (0%)
XY DSD Complete XY GD 21 11 (52.4%) 10 (47.6%)
Partial XY GD 37 7 (18.9%) 30 (81.1%)
XY ovotesticular DSD 5 2 (40.0%) 3 (60.0%)
CAIS 71 50 (70.4%) 21 (29.6%)
PAIS 35 18 (51.4%) 17 (46.6%)
3β-HSD 2 2 (100%) - (0%)
17β-HSD III 11 11 (100%) - (0%)
5α-RD II 4 4 (100%) - (0%)
17α-hydroxylase/17,20-lyase 1 - (0%) 1 (100%)
Other androgen synthesis defects 2 - (0%) 2 (100%)
XY DSD not classified 8 - (0%) 8 (100%)
Severe hypospadias 25 - (0%) 25 (100%)
XX DSD XX GD 20 - (0%) 20 (100%)
XX ovotesticular DSD 1 - (0%) 1 (100%)
CAH 226 156 (69.0%) 70 (31.0%)
XX males 6 3 (50.0%) 3 (50.0%)
In the add-on group of 121 XY CAH, diagnoses were genetically verified in 81.8%; aDiagnosis based on clinical and biochemical findings without positive genetic
test results
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participants’ professions varied, but no ESS data for
comparison were available. A detailed description is pre-
sented in Table 6.
In total, 17.8% of the dsd-LIFE cohort had contact
with support groups in the last 12 months, varying be-
tween 4.4% in France and 35.3% in the Netherlands. Of
these, 42–84% had contact via the Internet at least a few
times, and 42–89% had contact in face-to-face meetings
at least a few times.
Assessment of data quality
A total of 47 out of 1040 DSD participants (4.5%) did
not respond to the patient-reported outcome question-
naires. The non-completion rate ranged from 0% (0/107)
in Poland to 7.6% (19/231) in the Netherlands. A de-
tailed overview of total non-response to the standardized
instruments is shown in Table 7. The percentage of non-
response to any entire questionnaire was 5–6% for the
WHO-QOL-Bref, HADS, Adult ADHD Self-Report
Scale (ASRS), Autism Spectrum Quotient (AQ10), RSES,
and CSQ4. For the UGDS, the non-response rate for the
entire questionnaire was 24% for the female version and
47% for the male version. Because several participants
completed both female and male versions of this ques-
tionnaire, these percentages are based on all 1040 partic-
ipants with DSD in the cohort. The Experiences in Close
Relationships - Revised (ECR-RS) was not completed by
1.1% of subjects.2 The frequency of missing items and
missing sub-scores in completed questionnaires was less
than 1.5% except for the UGDS scales, where 24.1% (fe-
male version) and 38.5% (male version) of the items
were missing from the completed questionnaires (data
not shown). Medical history was mandatory and was
supplied by 99.5% of the participants. Very few partici-
pants did not meet in person with the study nurse or the
physician but were willing to answer the online PRO at
home. These participants were included in the study
because diagnoses and data on medical history could be
obtained from the medical records.
A total of 928 (89.2%) of the 1040 DSD participants
underwent at least part of the physical examination.
Participation in the general examination by diagnosis
group, country and gender is shown in Table 8. No rele-
vant differences in the subgroups were found except for
a lower participation rate in Sweden (65.6%, 80/122),
whereas in Poland and the United Kingdom, all parti-
cipants had at least a partial general examination. Partici-
pation in the gynaecological and urological examination is
also shown in Table 8. Approximately one-half (346/717,
48.3%) of the females and 71.1% (221/311) of the males
took part in the respective examinations. Across the
countries, there was large variation in participation in
gynaecological and urological examinations, reaching
from none in the UK to almost all participants in
Poland (both males and females). Participation in the
examinations across diagnosis groups was more evenly
distributed around the respective mean participation
rate with the exception of the more frequent gynaeco-
logical examination in XY DSD females (92/142, 64.8%).
In the group of XX CAH males, only 1 out of 5 took
part in the urological examination. Metabolic parameters
for 886 persons (85.2%) and hormones for 772 parti-
cipants (74.2%) were determined. Ultrasound was per-
formed on 380 (36.5%) of all 1040 DSD participants,3
a spermiogramme was evaluated for 50 participants, a
Dexa scan was carried out on 613 (58.9%) partici-
pants, and a BIA was performed on 283 participants
(27.2%). Carotid IMT measurements were taken on
208 participants (20.0%).
Retrospective data regarding the specific condition and
treatment were available for 480/1040 (46.2%) of the
participants. For the Turner group (152/301, 50.5%), the
XY DSD group 108/222, 48.6%), the CAH group (131/
226, 57.9%) and the smaller groups (including 47,XYY,
Table 7 Frequencies of missing questionnaires, sub-scores and items of standardized instruments according to diagnosis groups
% Non-response to entire questionnaire
Total CAH XY DSD Klinefelter Turner Othera
WHO-QOL-Bref 4.9 4.9 2.7 5.5 5.7 6.9
HADS 5.1 4.9 2.7 6.0 6.0 6.9
ASRS 5.4 4.9 3.2 6.4 6.3 6.9
AQ10 5.4 4.9 3.2 6.4 6.3 6.9
Rosenberg self esteem 5.6 4.9 3.6 6.4 6.6 6.9
CSQ4 6.3 4.9 3.2 8.3 7.0 11.0
UGDS female 24.3 14.2 16.2 44.0 22.3 30.1
UGDS male 47.2 51.1 33.9 32.1 65.8 43.8
ECR-RSb 1.1 0.0 2.5 1.8 0.5 0.0
aThese include the groups 47,XYY, XX gonadal dysgenesis, XX ovotestis, 46,XX, and 45,X/46,XY + other Y
bThe ECR-RS was only answered by participants who answered “yes” to the question: “Have you ever had a “romantic” relationship?” A total of 700 participants
(67.3%) answered yes, while 273 (26.3%) answered “no”, and 67 (6.4%) did not answer the question
Röhle et al. BMC Endocrine Disorders  (2017) 17:52 Page 20 of 26
XX DSD, 46, XX, and 45,X/46,XY + other Y: 46/73,
63.0%), the availability of at least some retrospective data
was approximately the same. For the Klinefelter group,
the availability of data was considerably lower (43/218,
19.7%). Gonadal histology was available for 123/1040
participants (11.8%), and for 500/1040 subjects (48.1%),
self-reported information or data from medical reports
were available regarding former condition-specific
surgeries.
Discussion
The study sample
The dsd-LIFE consortium was able to recruit a large
comprehensive DSD study population with 1040 partici-
pants. The initial sample size calculation had anticipated
1500 participants, but the size of the subgroups of the
1040 participants are large enough for adequate statis-
tical analysis. It was easiest to recruit female participants
with Turner syndrome and congenital adrenal hyperpla-
sia (CAH) and men with Klinefelter syndrome and sam-
ple size was sufficient in these groups. The number of
recruited participants with these specific diagnoses is
consistent with the incidence of the diagnoses. Most pa-
tients were recruited with Turner syndrome (1:2500)
followed by Klinefelter (1:500–1000), CAH (1:15,000)
and XY DSD conditions (1:25–150,000). The group of
XY DSD cases included the least common diagnoses
that were clinically and/or genetically sub-classified. A
total of 222 participated with only one third living in
male gender (n = 73), covering a wide range of clinical
diagnoses. Despite prolongation of the recruitment
period for this group, it was most difficult to engage par-
ticipants with XY-DSD conditions except for the centres
in France, Poland and the Netherlands, which had spe-
cialized clinics for this group. Sufficient numbers for
statistical analysis were achieved for the diagnoses of
complete androgen insensitivity (CAIS), partial androgen
insensitivity (PAIS), XY gonadal dysgenesis and 45,X/
46,XY conditions but not for XY androgen synthesis de-
fects. We conclude that despite the labelling of the study
as dsd-LIFE, the group most closely associated with the
term “disorders of sex development” was the most diffi-
cult to recruit. Adults with the condition appear to have
less access to specialized centres or clinics, and appro-
priate treatment appears to be least efficient in this
group [46]. We speculate that less regular contact and
more variation in health care among this group may also
contribute to some alienation. Equally, we were unable
to recruit a sufficient number of participants with XX GD.
We used mixed ways of recruitment via the medical
Table 8 Participation in medical exams: general physical examination, gynaecological exam, urological exam per diagnosis group,
country and gender
General physical examination Gynaecological examinationa Urological examinationc
Participation: total sample (%) Participation: female gender (%) Participation: male gender (%)
Diagnosis group
Turner syndrome 276/301 (91.7%) 123/301 (40.9%) Not applicable
Klinefelter syndrome 186/218 (85.3%) 0/1 144/212 (32.1%)
XY DSD conditions 191/222 (86.0%) 92/142 (64.8%) 59/73 (80.8%)
CAH 210/226 (92.9%) 103/221 (46.6%) 1/5 (20.0%)
Other conditionsa 65/73 (89.0%) 28/52 (53.8%) 17/21 (81.0%)
Country
Germany 236/244 (96.7%) 94/182 (51.6%) 46/56 (82.1%)
France 258/274 (94.2%) 139/231 (60.2%) 32/43 (74.4%)
The Netherlands 204/250 (81.6%) 23/153 (15.0%) 59/97 (64.8%)
Poland 107/107 (100%) 44/45 (97.8%) 61/62 (98.4%)
Sweden 80/122 (65.6%) 46/73 (63.0%) 23/49 (46.9%)
The United Kingdom 43/43 (100%) 0/33 0/10
Gender
Female 647/717 (90.2%) 346/717 (48.3%) c
Male 270/311 (86.8%) b 221/311 (71.1%)
Other 11/12 (91.7%) b c
aThese include the groups 47,XYY, XX gonadal dysgenesis, XX ovotestis, 46,XX males, and 45,X/46,XY + other Y
bParticipation in gynaecological examination was evaluated only in females. Nevertheless, one male participant in Germany and in Poland as well as three
participants with other gender received a gynaecological examination
cParticipation in urological examination was evaluated only in males. Nevertheless, one female participant in Poland as well as four participants with other gender
received a urological examination
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centers, website, support groups with the aim to reach as
many as possible individuals with rare diagnoses. More-
over, analysis of contact/membership of a support group
as an influencing factor on outcomes is planned. It could
be shown that the most efficient means of recruitment
were direct contact and information provision about the
study in the clinics, leading to a participation rate of 76%.
The least successful means of recruitment was contact by
mail, through support groups and website, with a partici-
pation rate of 22%, 24% and 0% respectively.
All participants could be classified according to the
Chicago classification. However, for some participants
with very unusual clinical presentation or unusual
chromosomal or genetic findings, correct classification
became a challenge. This was relevant, for example, in
the 45,X/46,XY subgroup presenting with a non-
androgenized Turner phenotype and individuals with
androgenization. The latter group clinically resembles
the XY DSD conditions and could be assigned to this
group for most analyses. Similarly, the classification of
46,XX males and 47,XYY males proved to be difficult:
clinically, these individuals are similar to Klinefelter
males because they all display testicular dysgenesis and
could be included in this group for outcome analyses.
Moreover, the 46,XX gonadal dysgenesis patients in-
cluded in the XX DSD subgroup are very different from
46,XX females with androgen effects due to CAH and
should be considered as a separate group. Finally, 46,XX
individuals with 21-OHD or 11ß-OHD deficiency living
as males may be included or excluded in outcome ana-
lyses depending on the specific research question. We
concede that the classification system from the Chicago
Consensus Conference was very helpful in terms of a
conceptual frame of reference. However, individual cases
may still be difficult to allocate to one of the major
groups. Any classification must be adapted to the pur-
pose at hand, be it research, patient care or public
communication.
Participation in different parts of the study
Participation in medical history and retrospective chart
review
Partial to complete data on contemporary and past med-
ical history from personal encounters with the physi-
cians were obtained for 99.5% of the participants.
Retrospective medical data from the chart review ad-
dressing the time of diagnosis and past treatment were
obtained for only 46.2% of the participants. In the cen-
tres focusing on adult care, charts from previous treat-
ment in childhood were not available. Moreover, for
older participants, previous charts were not available be-
cause they were destroyed after 30 years in accordance
with hospital regulations.
Participation in medical examinations
Most of the dsd-LIFE participants did take part in the
general examination, with no relevant differences among
diagnosis groups, gender or country. The participation
rate in gynaecological or urological examinations varied
between 15 and 97.8% and 46.9–98.4%, respectively. The
participation rate in these intimate exams was highest in
the XY DSD group, which may be interpreted as an indi-
cation of these participants’ need for gynaecological/uro-
logical follow-up and counselling. The participation rate
in the Dexa scans (58.9%) was high, demonstrating that
bone health is an issue for many persons with DSD con-
ditions. The participation rate was lowest for the add-
itional exams, such as genital ultrasound (36.5%), BIA
(27.2%), carotid IMT (20%) and spermiograms (4.8%).
Response rate of the PRO
The rate of non-response to the entire PRO part of the
dsd-LIFE was very low (4.5%). Especially, the standard-
ized instruments used in the study showed almost
complete response rates. The only exception was the
UGDS, which had a non-response rate of 24.3% for the
female and 47.2% for the male version. It is not entirely
clear why questions regarding gender dysphoria were so
often left unanswered. The UGDS was originally
designed for transgender individuals without DSD but
has been used without problems for people with DSD as
well [47]. The low rate of responses to this particular in-
strument might indicate that there were misunderstand-
ings or confusion regarding the items among our
participants. Originally, the scale was presented in two
gender-specific versions for those who live as female
gender and those who live as male gender. In contrast to
this presentation, i.e., in the German network study, the
dsd-LIFE consortium wanted to allow people with non-
binary identities (not identifying as either male or female)
[48] to respond to items of both the male and female ver-
sions. This, however, may have resulted in people consid-
ering many questions as not applicable. For instance,
persons identifying as females—most of our sample—may
have omitted answers to all questions for males, but, being
in a non-answering mode (the first half of the question-
naire considered questions for males), they may have
omitted answers to questions for females as well.
We conclude that in general, most participants showed
a very positive attitude toward answering the question-
naires and sharing their views on QoL, psychological
well-being, treatment experiences, sexuality and ethical
considerations.
Homogeneity/heterogeneity of countries
The characteristics that were heterogeneous among the
dsd-LIFE countries were age, gender and diagnosis. Un-
equal distributions of diagnoses, age groups and gender
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per country may be explained by varied focuses of clin-
ical care, research interests or access of dsd-LIFE study
personnel to clinics in the centres. Therefore, the condi-
tion groups were not evenly distributed among all cen-
tres; all analysis concerning country differences must be
controlled for the effects of the diagnosis, and vice versa.
Representativeness and limitations
The study sample is a convenience sample recruited by
the specialized study centres with different clinical foci
and in a variable proportion per country via support
groups. A participation rate of 36% of all eligible persons
in each centre cautions against generalizability. The par-
ticipation rate ranged from 30.0% in the Netherlands to
54.4% in Sweden. Reasons for these differences are most
likely explained by different approaches towards recruit-
ment. Compared to the ESS sample, the sample for the
current study was younger; the mean age was 32.36 years
(SD 13.57) compared to the mean age of the ESS, which
ranged from 48.70 years (SD 18.57) in Germany to
51.83 years (SD 19.12) in the United Kingdom. These
age differences might be explained by the fact, that only
in the recent years specialized clinics for adults with
DSD conditions have been installed in several European
countries. Patients are refered there mainly through
transition programmes. Subsequently, few older patients
are followed in these clinics. Most participants in the
current analysis lived in an urban environment (large
city to town), had a slightly higher education level and
were satisfied or coping well on their present income.
The sample size of females was approximately double
that of males. Only a few participants reported to have a
gender other than male or female; those participants
were recruited in Germany and the Netherlands. In
those two countries, there is—perhaps more than in the
other countries—discussion in support groups and
among the general public on the acknowledgement of
non-binary identities. For instance, in a Dutch study on
the prevalence of gender dysphoria, 3–4% reported to
have an ambivalent gender identity (equal identification
with the male and female genders) [49]. However, a se-
lection bias such as that in our study is well known from
previous studies in clinical samples. This study has
attempted to document at least the number of potential
participants from hospital data identifying potential par-
ticipants, who were all approached and informed.
Through this process, numbers of contacted persons,
ways of contact and participation rate could be retrieved.
Unfortunately, specific information on the diagnoses of
non-participants and their reasons not to participate
could not be obtained because the ethical restrictions
did not allow any data on non-participants to be col-
lected. We are therefore unable to provide a non-
responder analysis.
Data quality
Overall, the data quality of the study is good because the
mandatory parts of the study, such as medical history
and PRO, showed very low rates of completely missing
data of 0.5% and 4.5%, respectively. Subsequently, for
most analyses of the cohort, there were ample data for
statistical analysis. In addition, for most rare diagnoses,
such as 45,X/46,XY, CAIS, PAIS, partial XY gonadal dys-
genesis and CAH, data are estimated to be adequate for
clinical recommendations. Only for some very rare diag-
noses, such as XY complete gonadal dysgenesis, XX go-
nadal dysgenesis and androgen synthesis defects, were
the numbers of participants and data insufficient for
statistical analysis. However, these rare diagnoses are of
special interest and will be described as case series.
Analyses and publication strategy
The main data analyses for the primary objectives will
be performed by the coordination centre for clinical
studies of the Charité Universitätsmedizin Berlin. Sec-
ondary analyses addressing specific areas of interest or
related to clinical subgroups will be performed by author
teams composed of members of the dsd-LIFE consor-
tium based on a statistical analysis plan and a written
publication proposal. In addition, the results will be pre-
sented to the dsd-LIFE recommendation groups that
augment the existing knowledge on health care for these
conditions with new information from the study. Dis-
semination strategies will include scientific publications,
presentations within the scientific community and asso-
ciations of health care professionals, support groups,
and other stakeholders and policymakers.
Conclusions
dsd-LIFE is the first and largest European cross-
sectional study including the majority of conditions
encompassed by the DSD classification. The data ana-
lyses will focus on issues that are important for the im-
provement of care and the development of clinical
recommendations for patients with these conditions,
such as hormone therapy, surgery, fertility, psychological
and social support, and psychosexual and ethical issues.
Moreover, the specific aspects of single conditions, such
as Turner syndrome and Klinefelter syndrome, 45,X/
46,XY, CAIS, PAIS and CAH will be considered for im-
provement of care. A special focus will be to analyse and
consider the participants’ views on the different issues.
Altogether, QoL, psychosexual issues, physical and men-
tal health and satisfaction with treatment, support and
helath services will be measured in the whole cohort
and in sub-samples if indicated. The data from this large
sample will provide a sufficient basis for evidence-based
recommendations for improvement of clinical care of in-
dividuals affected by a DSD condition.
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Endnotes
1ESISCED categories: 1: less than lower secondary; 2:
lower secondary; 3: lower tier upper secondary; 4: upper
tier upper secondary; 5: advanced vocational, sub-degree;
6: lower tertiary education, BA level; 7: higher tertiary
education, ≥ MA level
2The ECR-RS could be answered only by participants
who answered ―yes‖ to the question: ―Have you ever
had a “romantic” relationship?‖ A total of 700 partici-
pants (67.3%) answered yes, while 273 (26.3%) answered
―no‖ and 67 (6.4%) did not answer the question.
3In France, one participant received both ultrasound
examinations.
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